Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT04975997 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

939

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Dexamethasone
DRUG: Daratumumab
DRUG: Bortezomib
DRUG: Iberdomide
DRUG: Iberdomide
DRUG: Iberdomide
DRUG: Dexamethasone
DRUG: Daratumumab

Sponsor

Celgene